Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Aradigm demonstrates top line data from ORBIT-1 ARD-3100 Phase 2b study for bronchiectasis

Aradigm Corporation today announced positive top line data from its recently concluded Phase 2b study (Once-Daily Respiratory Bronchiectasis Inhalation Treatment - ORBIT-1) with Aradigm's ciprofloxacin for inhalation (CFI, ARD-3100, LipoquinTM) in patients with non-cystic fibrosis bronchiectasis (BE).

16 Jun 2011

Serious RSV infections may occur in previously healthy infants and children

For most parents, respiratory syncytial virus (RSV) isn't a familiar term. But it's a common cause of serious respiratory infections with a major impact on the health of infants and young children worldwide, according to a special CDC Review Article in the June issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

16 Jun 2011

Galectin strengthens cancer drug patent portfolio in Europe

Galectin Therapeutics Inc. today announced that the European Patent Office has granted the Company a new patent, No. 02731178.6, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer".

15 Jun 2011

Liver stiffness measurement could replace liver biopsy for evaluation of hepatitis C

Non-invasive tests for liver fibrosis, such as liver stiffness measurement or the FibroTest, can predict survival of patients with chronic hepatitis C, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

15 Jun 2011

FDA approves Abbott's CREON capsules for treatment of EPI due to cystic fibrosis

Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis.

15 Jun 2011

Abbott’s CREON receives FDA approval for infant-specific dose

Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON® (pancrelipase) Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). The CREON 3,000 units of lipase capsule provides the lowest dosage strength in the class approved by the FDA. This new option will enable more precise dosing titration in accordance with the Cystic Fibrosis Foundation guidelines for infant dosing.

14 Jun 2011

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced an exclusive worldwide licensing agreement that will add two distinct nucleotide analogues to Vertex's hepatitis C portfolio.

13 Jun 2011

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Vertex Pharmaceuticals Incorporated today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF).

10 Jun 2011

Study links mutations in essential genes with orphan diseases

Mutations in genes essential to survival are behind so-called orphan diseases, explaining in part why these diseases are rare and often deadly, according to a study appearing in The American Journal of Human Genetics.

10 Jun 2011

New article warns Asians about striking increase in asbestos-related deaths

An alarming new article in Respirology issues a serious warning of massive rises in deaths from asbestos-related lung diseases in Asia. Dr Ken Takahashi, Acting Director of the WHO Collaborating Center for Occupational Health, and his team put together important data on asbestos use in 47 Asian countries in this landmark article. Cyprus, Israel and Japan had the highest age-adjusted mortality rates in Asia.

10 Jun 2011

ST2 biomarker can help indicate prognosis in ambulatory cardiovascular patients

The novel cardiac biomarker ST2 was highlighted in a presentation at last month's 2011 Heart Failure Congress of the European Society of Cardiology in Gothenburg, Sweden. As this study and others have demonstrated, a patient's ST2 level can help a physician better predict prognosis in ambulatory, chronic heart failure patients, which can allow physicians to more appropriately tailor care.

10 Jun 2011

Promising results from VX-770 and VX-809 Phase 2 study for cystic fibrosis

Vertex Pharmaceuticals Incorporated and the Cystic Fibrosis Foundation today announced promising results from an ongoing Phase 2 study evaluating combinations of VX-770 and VX-809, potential medicines designed to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Hepatitis C virus (HCV)-associated liver disease continues to be the most common indication for liver transplantation (LT) in the United States accounting for nearly 50% of all liver transplants. Recurrence is universal in patients viremic at the time of transplantation with histological hepatitis developing in the majority of patients. Although the natural history of recurrent HCV is difficult to predict, it is widely accepted that cirrhosis from recurrent HCV occurs in up to 30% of patients within five years of transplantation.

8 Jun 2011

Positive results from RXi's NeuVax-trastuzumab Phase 2 trial on breast cancer presented at ASCO

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, presented Phase 2 efficacy results for NeuVax in combination with trastuzumab at the American Society of Clinical Oncology (ASCO) annual meeting.

8 Jun 2011

McGill researcher develops speedier technique for predicting protein folding pathways

Protein folding has nothing to do with laundry. It is, in fact, one of the central questions in biochemistry. Protein folding is the continual and universal process whereby the long, coiled strings of amino acids that make up proteins in all living things fold into more complex three-dimensional structures.

8 Jun 2011

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

Halozyme Therapeutics, Inc. and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous injectable formulation of Intrexon Corporation's recombinant human alpha 1-antitrypsin (rHuA1AT).

7 Jun 2011

Tβ4 activates Akt survival kinase and reduces heart attack damage

RegeneRx Biopharmaceuticals, Inc. has announced that researchers have shown that Tβ4 has more extensive beneficial effects on the myocardium after heart attack than previously reported.

7 Jun 2011

Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced updated data from its Phase 2 clinical trial of NeuVax at the American Society of Clinical Oncology (ASCO) annual meeting.

7 Jun 2011

FDA grants orphan drug designation for Aradigm's ciprofloxacin to manage bronchiectasis

Aradigm Corporation today announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ciprofloxacin for inhalation for the management of bronchiectasis (BE).

6 Jun 2011

Fibrosis News and Research

Further Reading

Aradigm demonstrates top line data from ORBIT-1 ARD-3100 Phase 2b study for bronchiectasis

Serious RSV infections may occur in previously healthy infants and children

Galectin strengthens cancer drug patent portfolio in Europe

Liver stiffness measurement could replace liver biopsy for evaluation of hepatitis C

FDA approves Abbott's CREON capsules for treatment of EPI due to cystic fibrosis

Abbott’s CREON receives FDA approval for infant-specific dose

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Study links mutations in essential genes with orphan diseases

New article warns Asians about striking increase in asbestos-related deaths

ST2 biomarker can help indicate prognosis in ambulatory cardiovascular patients

Promising results from VX-770 and VX-809 Phase 2 study for cystic fibrosis

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Positive results from RXi's NeuVax-trastuzumab Phase 2 trial on breast cancer presented at ASCO

McGill researcher develops speedier technique for predicting protein folding pathways

Intrexon, Halozyme partner to develop subcutaneous alpha 1-antitrypsin for A1AT deficiency

Tβ4 activates Akt survival kinase and reduces heart attack damage

Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011

FDA grants orphan drug designation for Aradigm's ciprofloxacin to manage bronchiectasis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News